UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Survival patterns of invasive lobular and invasive ductal breast cancer in a large population-based cohort with two decades of follow up

Breast (Edinburgh), 2021-10, Vol.59, p.294-300

2021

Volltextzugriff (PDF)

Progesterone receptor positivity is a predictor of long-term benefit from adjuvant tamoxifen treatment of estrogen receptor positive breast cancer

Breast cancer research and treatment, 2016-11, Vol.160 (2), p.313-322

2016

Volltextzugriff (PDF)

No clear effect of postoperative radiotherapy on survival of breast cancer patients with one to three positive nodes: a population-based study

Annals of oncology, 2015-06, Vol.26 (6), p.1149-1154

2015

Volltextzugriff (PDF)

Secondary cancer is the leading cause of death 15 years or more after diagnosis of early‐stage Hodgkin lymphoma

Hematological oncology, 2023-06, Vol.41 (S2), p.369-370

2023

Volltextzugriff (PDF)

Can we predict the risk for non-sentinel node metastases? Results from the Swedish Breast Cancer Registry on 23,053 patients

Breast (Edinburgh), 2017-03, Vol.32, p.S62-S63

2017

Volltextzugriff (PDF)

Long-term Effectiveness of Adjuvant Goserelin in Premenopausal Women With Early Breast Cancer

JNCI : Journal of the National Cancer Institute, 2009-03, Vol.101 (5), p.341-349

2009

Volltextzugriff (PDF)

Predictive role of plasma vascular endothelial growth factor for the effect of celecoxib in advanced non-small cell lung cancer treated with chemotherapy

European journal of cancer (1990), 2013-01, Vol.49 (1), p.115-120

2013

Volltextzugriff (PDF)

Abstract P3-01-10: Can we predict the risk for non-sentinel node metastases? Results from the Swedish breast cancer registry on 23053 patients

Cancer research (Chicago, Ill.), 2018-02, Vol.78 (4_Supplement), p.P3-P3-01-10

2018

Volltextzugriff (PDF)

Limited, But Not Eliminated, Excess Long-Term Morbidity in Stage I-IIA Hodgkin Lymphoma Treated With Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine and Limited-Field Radiotherapy

Journal of clinical oncology, 2022-05, Vol.40 (13), p.1487-1496

2022

Volltextzugriff (PDF)

Breast cancer hormone receptor levels and benefit from adjuvant tamoxifen in a randomized trial with long-term follow-up

Acta oncologica, 2024-07, Vol.63 (1), p.535-541

2024

Volltextzugriff (PDF)

Prolonged tamoxifen treatment increases relapse-free survival for patients with primary breast cancer expressing high levels of VEGF

European journal of cancer (1990), 2010, Vol.46 (9), p.1580-1587

2010

Volltextzugriff (PDF)

Breast cancer survival and incidence of second primary cancers after 30 years in a randomized study of two versus five years of adjuvant tamoxifen therapy

Breast (Edinburgh), 2023-10, Vol.71, p.63-68

2023

Volltextzugriff (PDF)

P120 - Can we predict the risk for non-sentinel node metastases? Results from the Swedish Breast Cancer Registry on 23,053 patients

Breast (Edinburgh), 2017-03, Vol.32, p.S62-S63

2017

Volltextzugriff (PDF)

No excess long‐term mortality in stage I‐IIA Hodgkin lymphoma patients treated with ABVD and limited field radiotherapy

British journal of haematology, 2020-03, Vol.188 (5), p.685-691

2020

Volltextzugriff (PDF)

0229 When do locoregional recurrencies occur and how common is contralateral breast cancer?

Breast (Edinburgh), 2009, Vol.18, p.S76-S76

2009

Volltextzugriff (PDF)

Immunohistochemistry compared to cytosol assays for determination of estrogen receptor and prediction of the long-term effect of adjuvant tamoxifen

Breast cancer research and treatment, 2011-04, Vol.126 (2), p.421-430

2011

Volltextzugriff (PDF)

Abstract P3-07-19: Progesterone receptor positivity is an independent predictor of long-term benefit from adjuvant tamoxifen treatment of estrogen receptor positive breast cancer

Cancer research (Chicago, Ill.), 2016-02, Vol.76 (4_Supplement), p.P3-P3-07-19

2016

Volltextzugriff (PDF)

9025 Expression of cyclooxygenase-2 in cytological material from patients with lung cancer

European journal of cancer supplements, 2009, Vol.7 (2), p.513-513

2009

Volltextzugriff (PDF)

RAB6C is an independent prognostic factor of estrogen receptor-positive/progesterone receptor-negative breast cancer

Oncology letters, 2020-01, Vol.19 (1), p.52-60

2020

Volltextzugriff (PDF)

Proteomics profiling identify CAPS as a potential predictive marker of tamoxifen resistance in estrogen receptor positive breast cancer

Clinical proteomics, 2015-03, Vol.12 (1), p.8-8, Article 8

2015

Volltextzugriff (PDF)

No clear effect of postoperative radiotherapy on survival of breast cancer patients with 1-3 positive nodes: A population-based study

Annals of oncology, 2015, Vol.26 (6), p.1149

2015

Volltextzugriff (PDF)

Low RAB6C expression is a predictor of tamoxifen benefit in estrogen receptor-positive/progesterone receptor-negative breast cancer

Molecular and clinical oncology, 2020, Vol.12 (5), p.415-420

2020

Volltextzugriff (PDF)

Akt2 expression is associated with good long-term prognosis in oestrogen receptor positive breast cancer

European journal of cancer (1990), 2013-04, Vol.49 (6), p.1196-1204

2013

Volltextzugriff (PDF)

Abstract P6-07-12: Akt2 expression is associated with good long-term prognosis in estrogen receptor positive breast cancer

Cancer research (Chicago, Ill.), 2012-12, Vol.72 (24_Supplement), p.P6-P6-07-12

2012

Volltextzugriff (PDF)

Can we predict the risk for non-sentinel node metastases? Results from the Swedish Breast Cancer Registry on 23,053 patients

EUROPEAN JOURNAL OF CANCER, 2016, Vol.57, p.S72

2016

Volltextzugriff (PDF)

1 – 25 von 34

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(29)
Mit Volltextzugriff
(34)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Medicin Och Hälsovetenskap
(18)
Science & Technology
(18)
Life Sciences & Biomedicine
(17)
Oncology
(14)
Humans
(12)
Female
(10)
Middle Aged
(10)
Breast Cancer
(9)
Cancer And Oncology
(9)
Cancer Och Onkologi
(9)
Adult
(8)
Treatment Outcome
(8)
Aged
(7)
Medicine
(7)
Tumors
(7)
Breast Neoplasms - Drug Therapy
(6)
Breast Neoplasms - Metabolism
(6)
Hematology, Oncology And Palliative Medicine
(6)
Medicin
(6)
Antineoplastic Agents, Hormonal - Therapeutic Use
(5)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Survival patterns of invasive lobular and invasive ductal breast cancer in a large population-based cohort with two decades of follow up

Progesterone receptor positivity is a predictor of long-term benefit from adjuvant tamoxifen treatment of estrogen receptor positive breast cancer

No clear effect of postoperative radiotherapy on survival of breast cancer patients with one to three positive nodes: a population-based study

Secondary cancer is the leading cause of death 15 years or more after diagnosis of early‐stage Hodgkin lymphoma

Can we predict the risk for non-sentinel node metastases? Results from the Swedish Breast Cancer Registry on 23,053 patients

Long-term Effectiveness of Adjuvant Goserelin in Premenopausal Women With Early Breast Cancer

Predictive role of plasma vascular endothelial growth factor for the effect of celecoxib in advanced non-small cell lung cancer treated with chemotherapy

Abstract P3-01-10: Can we predict the risk for non-sentinel node metastases? Results from the Swedish breast cancer registry on 23053 patients

Limited, But Not Eliminated, Excess Long-Term Morbidity in Stage I-IIA Hodgkin Lymphoma Treated With Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine and Limited-Field Radiotherapy

Breast cancer hormone receptor levels and benefit from adjuvant tamoxifen in a randomized trial with long-term follow-up

Prolonged tamoxifen treatment increases relapse-free survival for patients with primary breast cancer expressing high levels of VEGF

Breast cancer survival and incidence of second primary cancers after 30 years in a randomized study of two versus five years of adjuvant tamoxifen therapy

P120 - Can we predict the risk for non-sentinel node metastases? Results from the Swedish Breast Cancer Registry on 23,053 patients

No excess long‐term mortality in stage I‐IIA Hodgkin lymphoma patients treated with ABVD and limited field radiotherapy

0229 When do locoregional recurrencies occur and how common is contralateral breast cancer?

Immunohistochemistry compared to cytosol assays for determination of estrogen receptor and prediction of the long-term effect of adjuvant tamoxifen

Abstract P3-07-19: Progesterone receptor positivity is an independent predictor of long-term benefit from adjuvant tamoxifen treatment of estrogen receptor positive breast cancer

9025 Expression of cyclooxygenase-2 in cytological material from patients with lung cancer

RAB6C is an independent prognostic factor of estrogen receptor-positive/progesterone receptor-negative breast cancer

Proteomics profiling identify CAPS as a potential predictive marker of tamoxifen resistance in estrogen receptor positive breast cancer

No clear effect of postoperative radiotherapy on survival of breast cancer patients with 1-3 positive nodes: A population-based study

Low RAB6C expression is a predictor of tamoxifen benefit in estrogen receptor-positive/progesterone receptor-negative breast cancer

Akt2 expression is associated with good long-term prognosis in oestrogen receptor positive breast cancer

Abstract P6-07-12: Akt2 expression is associated with good long-term prognosis in estrogen receptor positive breast cancer

Can we predict the risk for non-sentinel node metastases? Results from the Swedish Breast Cancer Registry on 23,053 patients

Suchergebnisse filtern